CDKN2A/p16INK4a Antibody

About the Target

CDKN2A/p16INK4a is a target of interest in many antibody-based workflows. CDKN2A encodes p16INK4a, a key tumor suppressor protein belonging to the INK4 family, characterized by four ankyrin repeats critical for binding cyclin-dependent kinases 4 and 6 (CDK4/6). The primary function of p16INK4a is to inhibit CDK4/6 activity, preventing phosphorylation of the retinoblastoma protein (Rb), thereby halting cell cycle progression from the G1 to S phase through blocking the release of E2F transcription factors. Depending on the literature source, CDKN2A/p16INK4a may also be discussed as CDKN2A/p16INK4a and CDKN2.

Reported cellular context includes cytoplasm and nucleus, which can matter when signal is compared across treatments or changing cell states. Following CDKN2A/p16INK4a across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

CDKN2A/p16INK4a is commonly interpreted in the context of cancer, cell cycle, and aging research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cytoplasm and nucleus across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• cell-cycle linked differences in abundance, timing, or compartmental enrichment
• context changes tied to cellular senescence, long-term stress adaptation, or tissue aging

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for CDKN2A/p16INK4a. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in CDKN2A/p16INK4a reflect biology rather than handling. When interpreting CDKN2A/p16INK4a, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep CDKN2A/p16INK4a trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.